NO177226C - Analogifremgangsmåte for fremstilling av terapeutisk aktive arylalkylaminer - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive arylalkylaminer

Info

Publication number
NO177226C
NO177226C NO913469A NO913469A NO177226C NO 177226 C NO177226 C NO 177226C NO 913469 A NO913469 A NO 913469A NO 913469 A NO913469 A NO 913469A NO 177226 C NO177226 C NO 177226C
Authority
NO
Norway
Prior art keywords
denotes
group
alkyl
optionally substituted
hydrogen
Prior art date
Application number
NO913469A
Other languages
English (en)
Other versions
NO913469L (no
NO177226B (no
NO913469D0 (no
Inventor
Xavier Emonds-Alt
Pierre Goulaouic
Vincenzo Proietto
Didier Van Broeck
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26228221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO177226(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9011039A external-priority patent/FR2666335B1/fr
Priority claimed from FR9107824A external-priority patent/FR2678267B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO913469D0 publication Critical patent/NO913469D0/no
Publication of NO913469L publication Critical patent/NO913469L/no
Publication of NO177226B publication Critical patent/NO177226B/no
Publication of NO177226C publication Critical patent/NO177226C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO913469A 1990-09-05 1991-09-04 Analogifremgangsmåte for fremstilling av terapeutisk aktive arylalkylaminer NO177226C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9011039A FR2666335B1 (fr) 1990-09-05 1990-09-05 Arylalkylamines, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR9107824A FR2678267B1 (fr) 1991-06-25 1991-06-25 Arylalkylamines, procede pour leur preparation et compositions pharmaceutiques les contenant.

Publications (4)

Publication Number Publication Date
NO913469D0 NO913469D0 (no) 1991-09-04
NO913469L NO913469L (no) 1992-03-06
NO177226B NO177226B (no) 1995-05-02
NO177226C true NO177226C (no) 1995-08-09

Family

ID=26228221

Family Applications (1)

Application Number Title Priority Date Filing Date
NO913469A NO177226C (no) 1990-09-05 1991-09-04 Analogifremgangsmåte for fremstilling av terapeutisk aktive arylalkylaminer

Country Status (27)

Country Link
US (2) US5236921A (no)
EP (1) EP0474561B1 (no)
JP (1) JP2620435B2 (no)
KR (1) KR100194823B1 (no)
AT (1) ATE174332T1 (no)
AU (1) AU657272B2 (no)
BR (1) BR9103802A (no)
CA (1) CA2050639C (no)
CZ (1) CZ285994B6 (no)
DE (1) DE69130597T2 (no)
DK (1) DK0474561T3 (no)
ES (1) ES2127722T3 (no)
FI (1) FI98457C (no)
GR (1) GR3029435T3 (no)
HK (1) HK1005290A1 (no)
HU (2) HU222351B1 (no)
IE (1) IE913082A1 (no)
IL (1) IL99320A (no)
LV (1) LV10606B (no)
MY (1) MY142065A (no)
NO (1) NO177226C (no)
NZ (1) NZ239661A (no)
PL (1) PL167994B1 (no)
PT (1) PT98849B (no)
RU (1) RU2070196C1 (no)
SG (1) SG47703A1 (no)
UA (1) UA27224C2 (no)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830863A (en) * 1988-06-20 1998-11-03 Merrell Pharmaceuticals Inc. Neurokinin A antagonists
US6218364B1 (en) 1988-06-20 2001-04-17 Scott L. Harbeson Fluorinated neurokinin A antagonists
ZA906188B (en) * 1989-08-10 1991-06-26 Merrell Dow Pharma Cyclic neurokinin a antagonists
FR2676053B1 (fr) * 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
FR2688218A1 (fr) * 1992-03-03 1993-09-10 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2688219B1 (fr) * 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
US5391819A (en) * 1992-09-30 1995-02-21 Merck & Co., Inc. Process of making chiral 2-aryl-1,4-butanediamine derivatives as useful neurokinin-A antagonists
US5583134A (en) * 1992-09-30 1996-12-10 Sanofi 1-azoniabicyclo[2.2.2] octanes and pharmaceutical compositions in which they are present
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
AU693087B2 (en) * 1993-01-28 1998-06-25 Merck & Co., Inc. Spiro-substituted azacycles as tachykinin receptor antagonists
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
HU224496B1 (hu) * 1993-05-06 2005-10-28 Merrel Dow Pharmaceuticals Inc. Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények
GB9310066D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
AU7947594A (en) * 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US6869957B1 (en) 1993-11-17 2005-03-22 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
GB9325074D0 (en) * 1993-12-07 1994-02-02 Zeneca Ltd Bicyclic heterocycles
US5589489A (en) * 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
EP0739336B1 (en) * 1994-01-13 1998-08-26 MERCK SHARP & DOHME LTD. Gem-disubstituted azacyclic tachykinin antagonists
GB2287404A (en) * 1994-03-15 1995-09-20 Pfizer Antiinflammatory and analgesic compositions
FR2717477B1 (fr) * 1994-03-18 1996-06-07 Sanofi Elf Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717478B1 (fr) * 1994-03-18 1996-06-21 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717802B1 (fr) * 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
FR2718136B1 (fr) * 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
GB9408872D0 (en) * 1994-05-03 1994-06-22 Zeneca Ltd Heterocyclic compounds
PL180866B1 (pl) * 1994-07-12 2001-04-30 Lilly Co Eli Nowy trihydrat dichlorowodorku (R)-3-(1H-indol-3-ilo)-1-[N-(2-metoksybenzylo)acetyloamino]-2-[N-(2-(4-(piperydyn-1-ylo)piperydyn-1-ylo)acetylo)amino]propanu
WO1996004266A2 (de) * 1994-08-03 1996-02-15 Asta Medica Aktiengesellschaft Indol-, indazol-, pyridopyrrol- und pyridopyrazol-derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender wirkung
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
AU693936B2 (en) 1994-08-25 1998-07-09 Merrell Pharmaceuticals Inc. Novel substituted piperidines useful for the treatment of allergic diseases
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
DE69534213T2 (de) * 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
EP0714891A1 (en) * 1994-11-22 1996-06-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists
FR2729952B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9505084D0 (en) * 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
AU697599B2 (en) * 1995-03-15 1998-10-08 Aventis Pharmaceuticals Inc. Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists
US6294537B1 (en) * 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
JP3950170B2 (ja) * 1995-04-13 2007-07-25 アベンティス・ファーマスーティカルズ・インコーポレイテッド タキキニン受容体アンタゴニスト活性を有する新規な置換されたピペラジン誘導体
US5716970A (en) * 1995-04-27 1998-02-10 Pharmacia & Upjohn Company Diuretic compound
GB9508786D0 (en) 1995-04-29 1995-06-21 Zeneca Ltd Substituted heterocycles
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5719156A (en) * 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
CA2223239A1 (en) * 1995-06-06 1996-12-12 Schering Corporation Substituted benzene-fused hetero- and carbocyclics as neurokinin antagonists
FR2738245B1 (fr) * 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US5892039A (en) * 1995-08-31 1999-04-06 Schering Corporation Piperazino derivatives as neurokinin antagonists
FR2738819B1 (fr) 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
RU2135494C1 (ru) 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
PT882038E (pt) * 1996-02-21 2003-04-30 Aventis Pharma Inc N-metil-n-(4-(piperidin-1-il)-2-(aril)butil)benzamidas substituidas vantajosas para o tratamento de doencas alergicas
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
IL125605A0 (en) * 1996-02-21 1999-03-12 Hoechst Marion Roussel Inc Novel substituted n-methyl-n-(4(4-(1h-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5691362A (en) * 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
ES2202481T3 (es) * 1996-10-28 2004-04-01 Schering Corporation Arilalquilaminas sustituidas como antagonistas de neuroquinina.
US5968929A (en) * 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5945428A (en) * 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5977139A (en) * 1996-12-15 1999-11-02 Hoechst Marion Roussel, Inc. Carboxysubstituted cyclic carboxamide derivatives
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
CA2278309A1 (en) * 1997-01-21 1998-07-23 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
PE134599A1 (es) * 1997-11-21 2000-01-07 Schering Corp Oximas sustituidas como antagonistas en neuroquinina
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US6316445B1 (en) 1998-05-15 2001-11-13 Aventis Pharmaceuticals Inc. Carboxy substituted acylic carboxamide derivatives
FR2779429B1 (fr) * 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
BR9912013A (pt) * 1998-07-10 2001-04-10 Astrazeneca Ab Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto
GB9922521D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
FR2784377B3 (fr) * 1998-10-09 2000-11-17 Sanofi Sa Nouveaux composes derives d'ureidopiperidine, antagonistes selectifs des recepteurs nk3 humains, procede pour leur obtention et compositions pharmaceutiques les contenant
US6063926A (en) * 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
GB9826941D0 (en) * 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
US6433174B1 (en) * 1998-12-16 2002-08-13 Nippon Kayaku Kabushiki Kaisha Process for producing novel naphthyridine derivatives
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2347909A1 (en) * 1998-12-18 2000-06-22 Joseph B. Santella, Iii N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2057200A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1156807A4 (en) * 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
DE60010516T2 (de) * 1999-12-24 2005-05-12 Mitsubishi Rayon Co., Ltd. Verfahren zur herstellung von tetrahydropyranyloxyaminen
CA2413245A1 (en) 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
US6511994B2 (en) * 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
JP4557492B2 (ja) 2001-03-21 2010-10-06 ファーマコペイア ドラッグ ディスカバリー， インコーポレイテッド Ｍｃｈ調節活性を有するアリール化合物およびビアリール化合物
PE20021081A1 (es) 2001-04-12 2002-12-18 Pharmacopeia Drug Discovery Aril y biaril piperidinas con actividad moduladora mch
AU2002259147A1 (en) 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
BR0212378A (pt) 2001-09-06 2004-10-19 Schering Corp Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
DZ3292A1 (fr) * 2001-09-13 2005-05-14 Solvay Pharm Gmbh Nouveaux composes de type 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]piperazine, methodes pour les preparer et medicaments renfermant cescomposes
CA2463626C (en) * 2001-10-17 2011-05-24 Schering Corporation Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA06001738A (es) 2003-08-15 2006-05-12 Lundbeck & Co As H Derivados de ciclopropilo como antagonistas del receptor nk3.
KR100997549B1 (ko) 2005-08-15 2010-11-30 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 길항제로서의 피페리딘 및 피페라진 유도체
US7592344B2 (en) * 2005-11-30 2009-09-22 Solvay Pharmaceuticals Gmbh NK1 and NK2-antagonists and compositions and methods of using the same
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
WO2007136323A1 (en) * 2006-05-18 2007-11-29 Albireo Ab A novel process suitable for large-scale production of phenyl propan derivatives of formula i
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant
CZ301920B6 (cs) * 2009-06-16 2010-07-28 Zentiva, K. S. Zpusob výroby (S)-4-methylamino-3-(3,4-dichlorfenyl)butan-1-olu
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3103516A (en) * 1959-07-29 1963-09-10 J-tertiaryaminq-lower alkyl-jb-meta-
NL6710477A (no) * 1966-07-29 1968-01-30
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
AT376669B (de) * 1982-11-26 1984-12-27 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thienylessigsaeureamid-derivate und pharmazeutisch vertraeglicher saeureadditionssalze davon
ZA842753B (en) * 1983-05-18 1984-11-28 Upjohn Co 2-dihydropyrrolyl-cycloalkyl-amide analgesics
US4920116A (en) * 1985-06-28 1990-04-24 Schering A.G. N-(aminoalkyl)-substituted(N or C alkyl)-aryl-4(methylsulfonylamino)benzamides
US4751327A (en) * 1985-06-28 1988-06-14 Xerox Corporation Photoconductive imaging members with unsymmetrical squaraine compounds
GB8618188D0 (en) * 1986-07-25 1986-09-03 Ici Plc Diamine compounds
EP0261842B1 (en) * 1986-09-17 1990-11-22 Dr. Lo. Zambeletti S.p.A. N1-acylated-(1-(phenyl or benzyl))-1,2-ethylene diamines
FR2613719B1 (fr) * 1987-04-10 1991-03-22 Sanofi Sa Derives aromatiques, leur preparation et leur utilisation comme antimicrobiens
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi

Also Published As

Publication number Publication date
GR3029435T3 (en) 1999-05-28
DK0474561T3 (da) 1999-08-16
LV10606A (lv) 1995-04-20
BR9103802A (pt) 1992-05-19
FI914174A (fi) 1992-03-06
US5350852A (en) 1994-09-27
PL167994B1 (pl) 1995-12-30
JPH04261155A (ja) 1992-09-17
LV10606B (en) 1996-04-20
DE69130597T2 (de) 1999-05-20
HUT59098A (en) 1992-04-28
RU2070196C1 (ru) 1996-12-10
EP0474561A1 (fr) 1992-03-11
AU657272B2 (en) 1995-03-09
JP2620435B2 (ja) 1997-06-11
PT98849A (pt) 1992-07-31
CA2050639C (en) 1997-12-02
US5236921A (en) 1993-08-17
FI914174A0 (fi) 1991-09-04
FI98457C (fi) 1997-06-25
UA27224C2 (uk) 2000-08-15
KR920006314A (ko) 1992-04-27
KR100194823B1 (ko) 1999-06-15
HU211893A9 (en) 1995-12-28
IL99320A0 (en) 1992-07-15
AU8354291A (en) 1992-03-12
ES2127722T3 (es) 1999-05-01
SG47703A1 (en) 1998-04-17
PT98849B (pt) 1999-02-26
CZ285994B6 (cs) 1999-12-15
NO913469L (no) 1992-03-06
NO177226B (no) 1995-05-02
CS272491A3 (en) 1992-03-18
PL291618A1 (en) 1992-08-24
ATE174332T1 (de) 1998-12-15
MY142065A (en) 2010-08-30
HU222351B1 (hu) 2003-06-28
CA2050639A1 (en) 1992-03-06
NO913469D0 (no) 1991-09-04
HK1005290A1 (en) 1998-12-31
EP0474561B1 (fr) 1998-12-09
FI98457B (fi) 1997-03-14
NZ239661A (en) 1994-06-27
DE69130597D1 (de) 1999-01-21
IL99320A (en) 1995-07-31
IE913082A1 (en) 1992-03-11

Similar Documents

Publication Publication Date Title
NO177226C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive arylalkylaminer
KR880007505A (ko) 큐마란 유도체, 그의 제법 및 용도
DE69114117D1 (de) Neue Verwendung von Peptidderivat.
FI103041B1 (fi) Menetelmä lääkeaineina käyttökelpoisten N-alkyleenipiperidinoyhdisteiden ja niiden enantiomeerien valmistamiseksi
KR960701048A (ko) 이소옥사졸리딘디온 유도체 및 그의 용도(isoxazolidinedione derivative and use thereof)
EA200000023A1 (ru) Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
ATE249457T1 (de) Indolderivate und ihre verwendung als serotoninrezeptor-liganden
ATE116311T1 (de) Tetramethylpiperidino-s-triazine.
ATE80885T1 (de) Thienyl-piperazinone, ihre herstellung und verwendung.
FI951398A (fi) Reniiniä inhiboivat N-(2-amino-2-oksoetyyli)butaanidiamidijohdannaiset
ATE211464T1 (de) 2-oxoindolin-derivate als cholecystokinin rezeptor antagonisten
ATE125530T1 (de) Neue indol- und indolin-verbindungen.
DK139889D0 (da) Heterocyklisk substituerede 5,7-dihydro-pyrrolooe3,2-faabenzoxazol-6-oner, fremgangsmaade til deres fremstilling samt laegemidler indeholdende disse
CA2378002A1 (en) Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates
NO912972L (no) Fremgangsmaate ved fremstilling av 6-alkylpyridazinderivater.
KR890013012A (ko) 신규 피페리도 벤즈 이미다졸 유도체

Legal Events

Date Code Title Description
MK1K Patent expired